Phase I Study of HRS-3005 in B-cell Malignancies

Summary

The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.

Timeline

Start

2026-06-03

Primary completion

2028-10

Completion

2028-12

Drugs

Indications